Research Cluster
Sleep, Circadian Rhythm, Stress & Recovery Peptides
Sleep and stress regulation are among the most neuropeptide-dense domains in mammalian physiology. The compounds documented in this cluster operate across overlapping systems—the orexin/hypocretin arousal network, the HPA stress axis, the suprachiasmatic nucleus circadian pacemaker, and the GABAergic and NPY-mediated stress buffering pathways—that interact continuously rather than in isolation. Understanding one system without the others produces an incomplete picture of how sleep, stress, and recovery are regulated at the peptide level.
A note on melatonin: it is the most widely used compound for sleep and circadian purposes worldwide and is not documented in this cluster because it is not a peptide. It is an indole hormone derived from tryptophan, regulated by the SCN, and available OTC in the United States (prescription in the EU and UK). The orexin system and desmopressin are the approved-drug anchors for this cluster; melatonin’s absence reflects the site’s scope rather than any editorial position about it.
The clinical evidence in this cluster is uneven in ways that map onto how the compounds have been developed. Compounds targeting the orexin and vasopressin systems have FDA-approved drugs and Phase III data. Compounds targeting the stress axis—NPY, PACAP, CRH—have robust human neuroscience but limited therapeutic development. The preclinical compounds here are some of the most mechanistically studied neuropeptides in basic neuroscience, despite having no clinical trial record.
Cluster at a Glance
13 compounds • 3 FDA-approved drugs (2 diagnostic, 1 therapeutic) • 4 Phase I/II clinical programs • 3 pilot/limited human data • 3 preclinical only • Highest neuropeptide density cluster on the site
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only
How These Compounds Relate
The 13 compounds in this cluster operate across four overlapping regulatory systems that do not function in isolation. The orexin–MCH axis is a reciprocal wake–sleep switch: orexin neurons fire during wakefulness and suppress REM, MCH neurons fire during REM and suppress wakefulness. The HPA stress axis—CRH at the top, cortisol at the bottom—activates arousal, disrupts sleep architecture, and is both driven and buffered by neuropeptides throughout the system: CRH and substance P amplify the stress response; NPY and oxytocin buffer it. The SCN circadian pacemaker coordinates the timing of the entire system, with VIP providing the intercellular synchronization signal and desmopressin addressing the nocturnal antidiuretic output of the circadian program. Galanin and cortistatin operate as state-specific sleep-promoting signals—galanin suppressing the noradrenergic arousal drive during NREM onset, cortistatin expressed during slow-wave sleep itself.
NPY and CRH are the most direct functional antagonists in this cluster. CRH drives the HPA stress cascade and promotes arousal and hypervigilance via direct amygdala and locus coeruleus actions. NPY suppresses locus coeruleus firing, attenuates HPA axis reactivity, and promotes NREM sleep. In the human stress resilience literature, NPY is the primary candidate for explaining why some individuals under extreme stress develop PTSD and others do not—lower NPY levels and impaired NPY-mediated buffering are among the most replicated biological correlates of PTSD vulnerability. The fact that PACAP, acting through PAC1 receptors in the amygdala, drives fear memory consolidation and is genetically associated with PTSD risk adds a third node to this CRH–NPY–PACAP stress circuit.
Desmopressin is the outlier in this cluster—the compound with the most direct approved sleep application, but operating through the most peripheral mechanism. It addresses sleep continuity by restoring the circadian antidiuretic signal that prevents nocturnal bladder pressure, rather than modulating sleep architecture or arousal systems directly. It is the only compound in this cluster approved specifically for a sleep-adjacent indication.
DSIP is the cluster’s most cautionary story. It was among the first peptides specifically proposed to induce sleep, studied in humans in IV trials, and generated enough positive findings to establish a research program. The inconsistent replication record over four decades—without a defined receptor, without a reproducible mechanism, and with studies that have been both positive and null across similar protocols—illustrates what happens when a compound’s initial findings in a highly controlled bioassay do not generalize to the complexity of the human sleep system.